Skip to content
AI.info

The Pulse

Tobicome releases Vigilance AI for drug-safety reporting

Vigilance AI helps assess drug and medical-device safety incidents and draft reports for regulators. Tobicome is recruiting companies to test its proposed time savings.

Tobicome releases Vigilance AI for drug-safety reporting

Tobicome says Vigilance AI can suggest whether drug and medical-device safety incidents need to be reported and draft reports for regulators, while leaving the final decision to a person. Tobicome said in its November 17 release that the service is aimed at manufacturers’ quality-assurance and safety-management departments, as well as medical institutions.

Source prtimes.jp

The company began accepting applications for a 30-minute demonstration using a simulated case and for a proof of concept to test the tool’s effects. There are separate versions for medicines and medical devices, using the relevant guidance and reporting forms.

From intake to draft

The system extracts details from safety information received from sources such as medical institutions, including the product name, event, health effects, outcome and circumstances. It displays whether the case might be reportable and possible deadlines, and distinguishes inferred information from items requiring confirmation.

For each assessment, the tool can suggest conclusions on whether reporting is needed, seriousness, causality or product relationship, and whether the event is known or unexpected. It displays a logic tree showing the route to a proposed decision, drawing on materials including regulations, guidance, past company cases, internal criteria and electronic product information.

Staff can check the supporting information, revise the assessment and confirm it. Manufacturers remain responsible for deciding whether and when to report. Draft reports can be copied by field, exported as CSV or printed; they require staff review and approval and are not submitted automatically.

Testing the time target

Tobicome has set a target of reducing work on a reportable case from a maximum of 243 minutes to 66 minutes with the tool. That is an estimated saving of 177 minutes, or about 73%, based on a scenario drawn from the company’s interviews with drug and medical-device manufacturers.

Actual results will vary with the work involved and will be tested in the proof of concept, according to the company. The interviews describe specific cases rather than conditions common to all manufacturers.

The proof of concept will compare AI-generated assessments with existing assessments of past cases, examining accuracy, time and the validity of the supporting reasons. Participants may also test the service alongside their regular work.

Tracking reports

A trend-analysis function displays monthly report counts against reference thresholds based on past averages and standard deviations. Users can view counts by product or event and inspect the associated cases.

The function provides reference information on changes in report counts; it does not automatically determine whether adverse-event rates have increased or whether a safety problem exists. In Japan, manufacturers must report qualifying safety information within prescribed deadlines, such as 15 or 30 days, depending on the product and event.

Sources

  1. PR TIMES
  2. Tobicome

Related stories

Explore

More articles